glaxosmithkline plc (GSK:London)
Executive Profile*
Robert Peter Wilson KCMGIndependent Non-Executive Director, Member of Corporate Administration & Transactions Committee, Member of Audit & Risk Committee, Member of Finance Committee, Member of Nominations Committee and Member of Corporate Responsibility Committee, GlaxoSmithKline plc |
| Age | Total Calculated Compensation | This person is connected to 71 board members in 3 different organizations across 10 different industries. See Board Relationships |
| 68 | $120,000 |
Background*
Sir Robert Peter Wilson, KCMG served as the Chief Executive Officer of Rio Tinto PLC (formerly, RTZ) from 1991 to 1997. Sir Wilson joined Rio Tinto in 1970. He began his career since 1966 as an Economist with Dunlop Ltd. He was appointed Knight Commander in the order of St Michael and St George (KCMG) in 2000 for services to British interests overseas. He serves as Chairman of the Board of Rio Tinto Group. Sir Wilson served as the Non Executive Chairman at BG Group PLC ...
Corporate Headquarters*980 Great West RoadBrentford, Middlesex TW8 9GS United Kingdom Phone: 44 20 8047 5000 Fax: 44 20 8047 7807 Board Members Memberships*Former Director and Executive Chairman of Rio Tinto Limited Former Non Executive Director Former Executive Chairman 1998-N/A Former Senior Non Executive Director 2002-N/A Former Non-Executive Director, Chairman of Finance Committee, Chairman of Nominations Committee, Chairman of Chairmans Committee, Member of Remuneration Committee and Member of Sustainability Committee 2002-N/A Former Non-Executive Chairman 2002-N/A Former Chairman of Remuneration Committee and Member of Audit Committee 2003-Present Independent Non-Executive Director, Member of Corporate Administration & Transactions Committee, Member of Audit & Risk Committee, Member of Finance Committee, Member of Nominations Committee and Member of Corporate Responsibility Committee
Education*Unknown/Other Education Harvard Business School Honorary Doctorate 2001 University Of Dundee BA University of Sussex Honorary Doctorate 1993 Exeter University
Other Affiliations* |
Annual Compensation*There is no Annual Compensation data available.Stock Options*There is no Stock Options data available.Total Compensation*
|
| Recently Viewed | |||
| GSK:LN | 1,773.00 GBp | +31.00 |  |
COMPETITOR COMPENSATION
| Name | Position/ Company | Compensation |
| John C. Martin Ph.D. | Chairman and Chief Executive Officer Gilead Sciences Inc. | $1.5M |
| Marijn E. Dekkers Ph.D. | Chairman of Management Board and Chief Executive Officer Bayer AG | €3.0M |
| Kenneth C. Frazier | Chairman, Chief Executive Officer and President Merck & Co. Inc. | $1.5M |
| Christopher A. Viehbacher | Chief Executive Officer, Director and Member of Strategy Committee Sanofi | €3.5M |
| Severin Schwan | Chief Executive Officer and Director Roche Holding AG | SFr.6.5M | Compensation as of Fiscal Year 2012. |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact GLAXOSMITHKLINE PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
